Omeros Co. (OMER) Shares Bought by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. grew its position in shares of Omeros Co. (NASDAQ:OMER) by 10.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 217,804 shares of the biopharmaceutical company’s stock after acquiring an additional 20,139 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.45% of Omeros worth $4,709,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. First Interstate Bank acquired a new stake in shares of Omeros in the third quarter valued at about $108,000. Legal & General Group Plc grew its stake in shares of Omeros by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 751 shares in the last quarter. Hanseatic Management Services Inc. grew its stake in shares of Omeros by 10,919.6% in the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Omeros in the third quarter valued at about $256,000. Finally, SG Americas Securities LLC grew its stake in shares of Omeros by 138.9% in the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 7,067 shares in the last quarter. Institutional investors own 49.71% of the company’s stock.

Shares of Omeros Co. (OMER) opened at $17.21 on Thursday. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. Omeros Co. has a 12 month low of $8.71 and a 12 month high of $27.09. The firm has a market capitalization of $867.91, a P/E ratio of -13.45 and a beta of 3.56.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to the consensus estimate of $17.82 million. During the same period in the prior year, the business earned ($0.34) EPS. The company’s quarterly revenue was up 91.9% on a year-over-year basis. equities research analysts forecast that Omeros Co. will post -0.98 earnings per share for the current year.

A number of equities research analysts have recently issued reports on the company. HC Wainwright set a $30.00 target price on Omeros and gave the company a “buy” rating in a research note on Thursday, December 14th. Maxim Group set a $24.00 target price on Omeros and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Finally, Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $34.14.

TRADEMARK VIOLATION WARNING: “Omeros Co. (OMER) Shares Bought by Schwab Charles Investment Management Inc.” was posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2018/01/18/omeros-co-omer-shares-bought-by-schwab-charles-investment-management-inc.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Institutional Ownership by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply